Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Offering people a choice for colorectal cancer screening

A study in the latest issue of Gut examines the effect of offering people a choice for colorectal cancer screening.

News image

Dr Carlo Senore and colleagues from Italy assessed the population coverage and diagnostic yield of offering an immunochemical fecal occult blood test to non-responders to a flexible sigmoidoscopy invitation.

A cohort study conducted in a population-based colorectal cancer screening program.

In this program, eligible men and women aged 58 or 60 are invited, with a personal letter signed by their general practitioner, to undergo an flexible sigmoidoscopy.

Bowel preparation is limited to a single enema self-administered at home.
 
Subjects in whom one distal polyp more than 5 mm or at least one adenoma is detected at flexible sigmoidoscopy are referred for colonoscopy.

19% underwent an immunochemical fecal occult blood test
Gut

The team reported that people who do not respond to the invitation to undergo an flexible sigmoidoscopy are invited to have an immunochemical fecal occult blood test.

Attendance rate and neoplasia yield were analyzed in 4 consecutive birth cohorts.

The research team found that overall participation rate for the flexible sigmoidoscopy invitation was 39% in Verona, and 30% in Turin.

Of the eligible non-responders to the flexible sigmoidoscopy invitation, 19% underwent an immunochemical fecal occult blood test.

As a result, the team reported that the proportion of people undergoing screening by flexible sigmoidoscopy or immunochemical fecal occult blood test was 55% in Verona, and 39% in Turin, with no gender differences in either center.

Immunochemical fecal occult blood test detected 8% of all advanced adenomas, and 20% of all colorectal cancers diagnosed at screening.

Dr Senore's team concludes, "A strategy involving the sequential offer of flexible sigmoidoscopy, and immunochemical fecal occult blood test is a feasible and efficient approach."

"Immunochemical fecal occult blood test in people not attending for flexible sigmoidoscopy increases screening uptake and detection of advanced adenomas and colorectal cancers."

Gut 2013; 62: 735-740 
10 April 2013

Go to top of page Email this page Email this page to a colleague

 26 July 2016 
Post-infectious IBS after C. diff
 26 July 2016 
Neighborhood variation in the use of laparoscopy for colon cancer
 26 July 2016 
Gut microbiota and IBD
 25 July 2016 
Steroids in eosinophilic esophagitis
 25 July 2016 
Prevention of post-ERCP pancreatitis
 25 July 2016 
Antibiotic prophylaxis for open colectomies
 22 July 2016 
Duodenal villous atrophy and celiac disease
 22 July 2016 
Fecal calprotectin and IBD
 22 July 2016 
Upper GI lesions at primary diagnosis in IBD
 21 July 2016 
Radiofrequency ablation in Barrett's
 21 July 2016 
HCV eradication and inflammation in cirrhotic patients
 21 July 2016 
Surveillance of Barrett's
 20 July 2016 
Nonselective β-blockers and survival in cirrhosis
 20 July 2016 
Adolescent body mass index and and colorectal cancer risk
 20 July 2016 
Genetic biomarkers and IBD treatment response
 19 July 2016 
Prevention of chemotherapy-induced nausea and vomiting
 19 July 2016 
Screening diabetic patients for NAFLD
 19 July 2016 
Longterm clinical follow-up of living liver donors
 18 July 2016 
Rectal neuroendocrine tumors
 18 July 2016 
Liver stiffness measurement in chronic liver disease
 18 July 2016 
Liver cancer prediction scores in Hep B
 15 July 2016 
Patient reported outcomes in celiac disease
 15 July 2016 
Tonsillectomy and IBD risk
 15 July 2016 
Trainee IBD education in the USA
 14 July 2016 
Screening for familial pancreatic cancer
 14 July 2016 
Fecal calprotection for IBD prognosis
 14 July 2016 
Perianal surgery risk in Crohn's
 13 July 2016 
Psychological comorbidity and postinfectious IBS
 13 July 2016 
Lung transplant outcomes in Hep C
 13 July 2016 
Graft selection strategy in living donor liver transplants
 12 July 2016 
Therapy for iron deficiency anemia in IBD
 12 July 2016 
Surveillance endoscopy in Barrett's esophagus
 12 July 2016 
Treatment of pediatric acute liver failure
 11 July 2016 
Transition to adulthood in celiac disease
 11 July 2016 
Disturbed sleep and IBS
 11 July 2016 
Factors that influence access to liver transplant
 08 July 2016 
Mortality and peptic ulcers
 08 July 2016 
Statins and cirrhosis in Hep B
 08 July 2016 
Genetic risk score and body mass index
 07 July 2016 
Predicting food triggers in eosinophilic esophagitis
 07 July 2016 
Predictors fecal transplant failure in C. diff infection
 07 July 2016 
Extraperitoneal vs transperitoneal colostomy for hernia
 06 July 2016 
Therapies for Hep B cure
 06 July 2016 
Hospital volume and liver cancer survival
 06 July 2016 
Adverse events after outpatient colonoscopy
 05 July 2016 
Colorectal surgery and dialysis
 05 July 2016 
Non-invasive scoring systems for fibrosis in NAFLD
 05 July 2016 
Exercise and gastroesophageal reflux
 04 July 2016 
Guidelines on PPI and NSAID prescription
 04 July 2016 
Rectal cancer surgery checklist
 04 July 2016 
Autoimmunity in eosinophilic esophagitis and families
 01 July 2016 
Outcome measures in celiac disease
 01 July 2016 
Growth factor activity and IBD
 01 July 2016 
Aspirin and colorectal cancer
 30 June 2016 
Staging system for familial adenomatous polyposis
 30 June 2016 
Antibiotics in children and obesity
 30 June 2016 
IBS-type symptoms in pediatric IBD
 29 June 2016 
Hep C eradication in people who inject drugs
 29 June 2016 
Anti-tumor necrosis factor in mothers and newborns
 29 June 2016 
Progression to esophageal carcinoma in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us